Akebia Therapeutics, Inc. filings document the regulatory record of a commercial-stage biopharmaceutical company focused on kidney disease therapeutics. Its 8-K reports include quarterly and annual operating results, Vafseo® commercialization updates, pipeline disclosures, Regulation FD presentations, and material agreements tied to licensing, supply, and corporate facilities.
Akebia’s proxy materials describe board composition, committee assignments, director elections, executive compensation, equity plans, and shareholder voting matters. The filing record also covers governance changes, Nasdaq-listed common stock matters, risk and business disclosures related to commercial products, clinical programs, collaborations, lease obligations, and capital-structure activity.
Akebia Therapeutics, Inc. reported that director Michael W. Rogers received new equity awards. He acquired 35,700 shares of common stock in the form of restricted stock units granted at no cash cost and not yet vested. He also received a stock option for 53,600 shares of common stock with an exercise price of $1.02 per share. Both the RSUs and the option vest in full on the first anniversary of the June 17, 2026 grant date, or immediately before the first annual stockholder meeting after that date, if earlier, subject to his continuous service. Following these awards, he directly holds 197,429 shares of common stock and 53,600 stock options.
Akebia Therapeutics director Ron Frieson received equity awards as part of his director compensation. He was granted 35,700 restricted stock units under the 2023 Stock Incentive Plan, increasing his direct common stock holdings to 165,200 shares. He was also granted stock options for 53,600 shares at an exercise price of $1.02 per share.
Both the RSUs and the stock options vest 100% on the first anniversary of the June 17, 2026 grant date, or earlier immediately before the first annual stockholders’ meeting after that date, if he continues serving the company through vesting.
Akebia Therapeutics’ stockholders held their 2026 annual meeting and approved several corporate matters. They elected three Class III directors – Adrian Adams, Michael Rogers and LeAnne M. Zumwalt – to serve until the 2029 annual meeting. Stockholders also approved a Share Increase Amendment to the certificate of incorporation, raising authorized capital stock from 375,000,000 to 525,000,000 shares and authorized common stock from 350,000,000 to 500,000,000 shares, with 102,504,108 votes for and 88,853,129 against. In advisory votes, stockholders approved named executive officer compensation and recommended that say-on-pay votes occur every year. They also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Akebia Therapeutics director Leanne M. Zumwalt received equity awards in the form of common stock and stock options. She was granted 35,700 shares of Common Stock as restricted stock units under Akebia’s 2023 Stock Incentive Plan, bringing her direct common stock holdings to 145,100 shares after the grant.
She was also granted a stock option for 53,600 shares of common stock with an exercise price of $1.02 per share, expiring on June 17, 2036. Both the RSUs and the option vest 100% on the first anniversary of the grant date, or earlier immediately before the first annual meeting of stockholders after the grant, if she continues serving the company.
Akebia Therapeutics, Inc. director Adrian Adams reported awards of equity-based compensation. He received 35,700 shares of common stock as restricted stock units that were granted at no cash price and increase his direct holdings to 236,200 common shares after the award.
Adams was also granted a stock option for 53,600 shares of common stock with an exercise price of $1.02 per share, expiring on June 17, 2036. Both the restricted stock units and the stock option are scheduled to vest in full on the first anniversary of the grant date, or earlier immediately before the first annual stockholder meeting after the grant, subject to his continuous service to the company.
AKEBIA THERAPEUTICS INC Schedule 13G: State Street Corporation reports beneficial ownership of 11,614,006 shares of common stock, representing 4.3% of the class as of 03/31/2026. The filing lists shared voting power of 11,269,922 and shared dispositive power of 11,614,006.
The filing names affiliated investment management entities and is signed by a State Street officer on 05/12/2026. This is a passive ownership disclosure under Schedule 13G reporting holdings and power classifications.
Akebia Therapeutics reported a Q1 2026 net loss of $9.1 million, reversing from net income of $6.1 million a year earlier, as total revenues declined to $53.5 million from $57.3 million. Product revenue was $52.0 million, with Auryxia contributing $36.2 million and Vafseo $15.8 million.
Cash and cash equivalents were $162.6 million, with total assets of $362.5 million and total liabilities of $335.1 million. Net cash used in operating activities was $21.2 million. Auryxia lost U.S. exclusivity in March 2025, and on March 11, 2026 a Teva generic was approved and has entered the market, adding new competitive pressure. Management believes current cash and expected revenues can fund the operating plan for at least twelve months from the filing date, but notes this depends on achieving anticipated Vafseo revenue.
Akebia Therapeutics reported a net loss of $9.1 million in the first quarter of 2026, reversing from net income of $6.1 million a year earlier. Total revenues were $53.5 million, down from $57.3 million, as lower Auryxia sales more than offset growth from Vafseo.
Vafseo net product revenues rose to $15.8 million from $12.0 million, helped by an approximate 60% increase in patients on therapy versus the end of Q4 2025 and about 28% more prescribers. Auryxia net product revenues declined to $36.2 million from $43.8 million, with the company expecting generic competition to expand and further reduce 2026 Auryxia revenues.
Operating costs increased as Akebia invested in its kidney disease pipeline, including Phase 2 trials for praliciguat and AKB-097 and a Phase 1 study of AKB-9090. Research and development expenses rose to $14.8 million and selling, general and administrative expenses to $30.4 million. Cash and cash equivalents were $162.6 million as of March 31, 2026, and the company expects these resources and cash from operations to fund its current operating plan for at least two years.
Akebia Therapeutics is asking stockholders to vote at its virtual 2026 annual meeting on June 17, 2026. The agenda includes electing three Class III directors, advisory votes on executive pay and the frequency of that vote, and ratifying Ernst & Young LLP as auditor for 2026.
A key proposal would amend the certificate of incorporation to increase authorized capital stock from 375,000,000 to 525,000,000 shares, and authorized common stock from 350,000,000 to 500,000,000. As of March 31, 2026, 267,898,415 common shares were outstanding and 321,611,965 shares were issued or reserved, leaving 28,388,035 unreserved. The board recommends voting in favor of all proposals and selecting "one year" for the say‑on‑pay frequency.